Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.


Despite the development of potent RAF/mitogen-activated protein kinase (MAPK) pathway inhibitors, only a fraction of BRAF-mutant patients benefit from treatment with these drugs. Using a combined chemogenomics and chemoproteomics approach, we identify drug-induced RAS-RAF-MEK complex formation in a subset of BRAF-mutant cancer cells characterized by primary… (More)
DOI: 10.1016/j.celrep.2014.07.010


  • Presentations referencing similar topics